#METABOLOMICS WORKBENCH hjyoo2_20200818_181947 DATATRACK_ID:2131 STUDY_ID:ST001467 ANALYSIS_ID:AN002442 PROJECT_ID:PR000999 VERSION 1 CREATED_ON August 27, 2020, 10:02 am #PROJECT PR:PROJECT_TITLE Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation PR:PROJECT_TITLE study PR:PROJECT_SUMMARY A multimodal approach was performed to investigate the effects of BST204 on the PR:PROJECT_SUMMARY alleviation of chemotherapy-induced cachexia. The targeted metabolome changed PR:PROJECT_SUMMARY with chemotheraphy-induced cachexia and the changes were reversed with potential PR:PROJECT_SUMMARY treatment of the cachexia. PR:INSTITUTE Asan medical Center, University of Ulsan College of Medicine PR:LAST_NAME Yoo PR:FIRST_NAME Hyun Ju PR:ADDRESS 88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea PR:EMAIL yoohyunju@amc.seoul.kr PR:PHONE 82-02-3010-4029 #STUDY ST:STUDY_TITLE Metabolites changes related to glucose-mediated energy production in ST:STUDY_TITLE chemotheraphy-induced cachexia ST:STUDY_SUMMARY Targeted metabolomics platforms included amino acids and metabolites related to ST:STUDY_SUMMARY glucose-mediated energy production. The targeted metabolome changed with ST:STUDY_SUMMARY chemotheraphy-induced cachexia, and the changes were reversed with potential ST:STUDY_SUMMARY treatment of the cachexia. .rdb files were included as raw data files where ST:STUDY_SUMMARY detailed information regarding MRM transitions and internal standards can be ST:STUDY_SUMMARY found. Several amino acids (Gly, Pro, Gln, Taurine) were analyzed after dilution ST:STUDY_SUMMARY because their peak intensities were too high. Thus their analysis was performed ST:STUDY_SUMMARY separately from other amino acids, and their rdb files were saved in separate ST:STUDY_SUMMARY rdb files. ST:INSTITUTE Asan medical Center, University of Ulsan College of Medicine ST:LAST_NAME Yoo ST:FIRST_NAME Hyun Ju ST:ADDRESS 88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea ST:EMAIL yoohyunju@amc.seoul.kr ST:PHONE 82-02-3010-4029 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Mus musculus SU:TAXONOMY_ID 10090 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS NTB NTB_1p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_2p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_3p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_4p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_5p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_6p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_1p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_2p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_3p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_4p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_5p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_6p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1p Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2p Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3p Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4p Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5p Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6p Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_4p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_1m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_2m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_3m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_4m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_5m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_6m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_1m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_2m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_3m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_4m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_5m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_6m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1m Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2m Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3m Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4m Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5m Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6m Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_4m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_1p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_2p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_3p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_4p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_5p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_6p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_1p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_2p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_3p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_4p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_5p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_6p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1p_2 Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2p_2 Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3p_2 Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4p_2 Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5p_2 Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6p_2 Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_1m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_2m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_3m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_4m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_5m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_6m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_1m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_2m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_3m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_4m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_5m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_6m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1m_2 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2m_2 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3m_2 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4m_2 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5m_2 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6m_2 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_1m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_2m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_3m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_4m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_5m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_6m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_1m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_2m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_3m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_4m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_5m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_6m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1m_1 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2m_1 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3m_1 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4m_1 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5m_1 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6m_1 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 #COLLECTION CO:COLLECTION_SUMMARY Mice were randomized into five groups (n = 10 each): untreated, CO:COLLECTION_SUMMARY non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); CO:COLLECTION_SUMMARY tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving CO:COLLECTION_SUMMARY 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving CO:COLLECTION_SUMMARY 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells CO:COLLECTION_SUMMARY (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of CO:COLLECTION_SUMMARY phosphate-buffered saline were subcutaneously implanted in the right flank of CO:COLLECTION_SUMMARY 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached CO:COLLECTION_SUMMARY 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was CO:COLLECTION_SUMMARY assigned and drug administration started for 5-FU and BST204 groups. BST204 CO:COLLECTION_SUMMARY (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South CO:COLLECTION_SUMMARY Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 CO:COLLECTION_SUMMARY mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; CO:COLLECTION_SUMMARY 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. CO:COLLECTION_SUMMARY BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: CO:COLLECTION_SUMMARY days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according CO:COLLECTION_SUMMARY to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our CO:COLLECTION_SUMMARY study was determined according to IACUC guidelines, which recommend euthanasia CO:COLLECTION_SUMMARY with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our CO:COLLECTION_SUMMARY study period was limited to day 11. At this point, the change in tumor volumes CO:COLLECTION_SUMMARY was up to 810%, and significant cachexia was observed. CO:SAMPLE_TYPE Blood (plasma) CO:COLLECTION_LOCATION muscle CO:STORAGE_CONDITIONS -20℃ #TREATMENT TR:TREATMENT_SUMMARY Mice were randomized into five groups (n = 10 each): untreated, TR:TREATMENT_SUMMARY non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); TR:TREATMENT_SUMMARY tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving TR:TREATMENT_SUMMARY 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving TR:TREATMENT_SUMMARY 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells TR:TREATMENT_SUMMARY (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of TR:TREATMENT_SUMMARY phosphate-buffered saline were subcutaneously implanted in the right flank of TR:TREATMENT_SUMMARY 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached TR:TREATMENT_SUMMARY 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was TR:TREATMENT_SUMMARY assigned and drug administration started for 5-FU and BST204 groups. BST204 TR:TREATMENT_SUMMARY (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South TR:TREATMENT_SUMMARY Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 TR:TREATMENT_SUMMARY mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; TR:TREATMENT_SUMMARY 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. TR:TREATMENT_SUMMARY BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: TR:TREATMENT_SUMMARY days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according TR:TREATMENT_SUMMARY to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our TR:TREATMENT_SUMMARY study was determined according to IACUC guidelines, which recommend euthanasia TR:TREATMENT_SUMMARY with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our TR:TREATMENT_SUMMARY study period was limited to day 11. At this point, the change in tumor volumes TR:TREATMENT_SUMMARY was up to 810%, and significant cachexia was observed. TR:TREATMENT 5-FU was injected intraperitoneally in 3-day cycles. BST204 was orally TR:TREATMENT administerd in 5-day cycles. TR:TREATMENT_DOSE 5-FU (50 mg/kg), BST204 (100 or 200 mg/kg) TR:ANIMAL_ENDP_EUTHANASIA study period was limited by day 11 TR:TREATMENT_COMPOUND 5-FU, BST204 #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Metabolites related to glucose-mediated energy metabolism were extracted using SP:SAMPLEPREP_SUMMARY LLE. Amino acids and bioamines were also extracted using LLE and underwent SP:SAMPLEPREP_SUMMARY chemical derivatization with phenylisothiocyante. SP:PROCESSING_STORAGE_CONDITIONS 4℃ SP:EXTRACTION_METHOD Liquid Liquid Extraction (LLE) #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Metabolites related to glucose-mediated metabolites were analyzed with LC-MS/MS CH:CHROMATOGRAPHY_SUMMARY (MRM) CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Agilent 1290 CH:COLUMN_NAME Synergi fusion RP (50 x 2 mm) CH:FLOW_GRADIENT 0% B for 5 min, 0% to 90% B for 2 min, hold at 90% B for 8 min, 90% to 0% B for CH:FLOW_GRADIENT 1 min, and then hold at 0% B for 9 min CH:FLOW_RATE 70 μL/min except for minutes 7 to 15, when it was 140 µL/min CH:COLUMN_TEMPERATURE 23 CH:SOLVENT_A 5 mM ammonium acetate in H2O CH:SOLVENT_B 5 mM ammonium acetate in ACN CH:INTERNAL_STANDARD 13C5-glutamine CH:SAMPLE_INJECTION 3 uL #ANALYSIS AN:ANALYSIS_TYPE MS AN:ACQUISITION_DATE 2018 May #MS MS:INSTRUMENT_NAME ABI Sciex 5500 QTrap MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_COMMENTS Metabolites related to glucose-mediated energy production MRM mode Analyst 1.52 #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS area ratio MS_METABOLITE_DATA_START Samples NTB_1p_2 NTB_2p_2 NTB_3p_2 NTB_4p_2 NTB_5p_2 NTB_6p_2 TB_1p_2 TB_2p_2 TB_3p_2 TB_4p_2 TB_5p_2 TB_6p_2 5FU_1p_2 5FU_2p_2 5FU_3p_2 5FU_4p_2 5FU_5p_2 5FU_6p_2 BST100_1p_2 BST100_2p_2 BST100_3p_2 BST100_4p_2 BST100_5p_2 BST100_6p_2 BST200_1p_2 BST200_2p_2 BST200_3p_2 BST200_4p_2 BST200_5p_2 BST200_6p_2 NTB_1m_2 NTB_2m_2 NTB_3m_2 NTB_4m_2 NTB_5m_2 NTB_6m_2 TB_1m_2 TB_2m_2 TB_3m_2 TB_4m_2 TB_5m_2 TB_6m_2 5FU_1m_2 5FU_2m_2 5FU_3m_2 5FU_4m_2 5FU_5m_2 5FU_6m_2 BST100_1m_2 BST100_2m_2 BST100_3m_2 BST100_4m_2 BST100_5m_2 BST100_6m_2 BST200_1m_2 BST200_2m_2 BST200_3m_2 BST200_4m_2 BST200_5m_2 BST200_6m_2 Factors Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:5FU | Sample Source:plasma Group:batch1 | Treatment:5FU | Sample Source:plasma Group:batch1 | Treatment:5FU | Sample Source:plasma Group:batch2 | Treatment:5FU | Sample Source:plasma Group:batch2 | Treatment:5FU | Sample Source:plasma Group:batch2 | Treatment:5FU | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:5FU | Sample Source:muscle Group:batch1 | Treatment:5FU | Sample Source:muscle Group:batch1 | Treatment:5FU | Sample Source:muscle Group:batch2 | Treatment:5FU | Sample Source:muscle Group:batch2 | Treatment:5FU | Sample Source:muscle Group:batch2 | Treatment:5FU | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle D-Glucose 658.263 619.76 489.655 745.636 779.412 607.375 541.667 536.058 514.706 642.254 444.751 451.902 352.941 318.501 205.425 322.296 475.309 349.593 594.972 515.228 500 541.985 662.162 745.798 368.7 591.011 588.372 401.515 622.449 442.553 138.42 199.24 74.18 105.92 105.86 93.8 89.49 88.49 85.2 92.05 95.64 114.55 31.81 65.74 54.28 65.89 85.65 62.74 106.24 103.33 96.06 91.81 96.27 103.2 96.61 162.52 85.95 117.17 90.64 139.56 Glucose 6-phosphate 1.958 2.417 1.79 2.166 1.643 1.61 2.094 1.976 1.968 1.997 2.64 1.921 0.81 1.171 0.953 0.889 1.091 1.014 1.581 1.456 1.272 1.829 0.995 1.758 1.197 1.555 1.542 1.22 1.634 1.669 142.16 2.85 1.51 1.81 2.49 29.15 59.08 29.67 47.71 15.83 4.24 14.9 0.89 2.28 0.47 1.19 3.03 6.94 15.81 19.12 1.99 1.07 13.37 1.02 8.73 20 5.71 13.41 5.16 18.67 Fructose 1,6-bisphosphate 0.265 0.236 0.228 0.152 0.193 0.191 0.511 0.412 0.33 0.513 0.525 0.362 0.24 0.131 0.129 0.137 0.142 0.148 0.492 0.273 0.194 0.239 0.171 0.239 0.185 0.336 0.204 0.165 0.247 0.185 40.65 0.74 0.8 1.11 1.75 11.83 16.89 12.16 14.99 6.01 2.27 7.31 0.28 0.62 0.15 0.51 1.05 2.04 5.35 7.56 1.03 0.42 4.3 0.51 2.22 8.2 1.77 5.89 1.26 8.73 3-Phosphoglyceric acid 0.866 1.053 0.781 0.576 0.509 0.684 1.094 1.096 0.887 0.961 1.105 0.899 0.723 0.403 0.62 0.499 0.535 0.604 0.591 0.557 0.382 0.491 0.503 0.54 0.639 0.701 0.658 0.693 0.597 0.723 10.85 1.03 0.7 0.77 1.44 3.67 5.76 4.43 3.74 1.19 2.7 2.93 0.36 0.19 0.52 1.01 0.63 0.48 1.98 2.38 0.68 0.44 1.22 0.77 1.97 3.67 1.18 2.72 0.62 2.21 Phosphoenolpyruvic acid 0.412 0.429 0.317 0.316 0.344 0.48 0.47 0.444 0.445 0.499 0.396 0.372 0.285 0.21 0.236 0.241 0.237 0.232 0.254 0.239 0.211 0.313 0.176 0.169 0.305 0.371 0.237 0.278 0.313 0.311 1.48 0.16 0.12 0.13 0.16 0.64 1 1.01 0.87 0.32 0.48 0.71 0.05 0.04 0.12 0.12 0.13 0.1 0.58 0.6 0.1 0.08 0.17 0.13 1.49 0.34 0.35 1.04 0.13 0.59 Pyruvic acid 85.97 107.485 61.724 93.267 79.902 60.954 75.49 69.328 68.169 73.481 77.405 74.538 56.704 79.391 81.368 47.461 54.527 46.748 95.178 64.407 34.86 54.73 61.556 69.958 85.676 82.938 77.528 74.811 58.511 65.619 29.68 36.65 24.59 30.69 27.99 25.54 18.67 17.18 16.49 27.25 27.07 27.62 9.39 15.32 12.69 21.73 26.84 18.67 20.51 17.82 27.22 27.12 19.69 27.22 17.31 30.21 33.2 27.42 18.67 34.93 L-Lactic acid 901.493 769.461 503.448 947.631 740.196 622.56 818.627 733.193 664.789 781.768 774.049 792.608 650.838 829.04 846.698 485.651 567.901 573.171 939.086 588.983 353.69 542.793 672.769 829.832 832.891 755.924 822.472 839.015 610.638 700.555 347.92 403.23 219.78 285.05 261.02 245.31 202.04 204.74 194.17 260.68 249.87 265.65 114.07 163.11 152.07 213.76 262.66 197.89 242.96 209.25 194.66 229.2 196.28 238.65 208.64 350.04 313.3 250.94 198.24 320 Citric acid 1029.851 1355.742 1314.371 1186.207 1384.804 1210.412 965.686 1076.923 1002.101 1445.07 1217.002 1177.528 111.732 224.041 176.581 133.726 213.992 211.382 697.97 521.186 671.756 779.279 356.979 686.975 587.678 613.483 484.848 577.551 374.468 325.323 6.41 10.35 23.42 3.75 4.56 3.2 5.33 4.27 4.67 3.48 3.59 3.86 5.8 3.96 6.76 3.79 3.31 3.73 4.71 5.21 4.93 5.46 4.06 3.83 4.97 4.84 5.04 2.67 3.16 3.22 Succinic acid 9.194 13.529 7.216 10.207 9.177 17.223 6.25 5.666 5.048 4.648 10.649 11.725 1.33 1.756 1.927 1.932 1.961 1.803 4.188 4.513 3.537 2.635 2.025 10.126 4.377 6.303 4.18 8.884 5.777 4.857 19.83 11.85 9.96 4.74 7.32 8.3 6.93 4.67 5.23 5.04 5.42 5.41 0.88 2.78 2.1 2.62 2.83 3.31 6.55 5.57 3.52 3.19 2.78 6.58 3.86 5.89 3.75 5.03 3.34 3.39 Fumaric acid 8.269 6.228 9.241 10.2 10.417 9.219 2.194 3.185 1.952 2.101 2.499 3.624 0.439 0.985 0.806 0.476 1.163 0.508 2.538 2.225 1.056 1.574 1.103 3.466 1.419 1.912 3.093 1.197 1.227 1.734 6.48 5.53 4.33 1.57 1.89 2.39 3.13 2.08 3.09 1.91 1.87 2.05 2.43 2.06 1.4 1.83 2.33 1.29 2.4 3.01 2.29 1.71 2.01 1.76 2.99 4.17 2 1.99 1.6 1.99 Malic acid 65.075 101.401 80.69 91.022 98.529 77.44 23.167 24.517 19.303 18.466 28.732 36.465 13.402 10.703 10.212 14.923 9.444 16.301 16.345 10.657 16.972 15 11.487 30.252 12.361 12.938 15.213 28.14 15.928 14.34 50.63 41.63 31.18 10.28 12.91 15.44 24.12 15.6 24.2 12.96 12.32 12.44 16.56 14.95 10.12 11.08 14.36 8.63 18.02 22.46 14.32 11.1 12.78 10.51 23.35 32.61 15.67 13.5 9.73 12.62 Adenosine monophosphate 0.151 0.386 0.171 0.11 0.098 0.125 0.101 0.112 0.06 0.096 0.058 0.062 0.098 0.225 0.255 0.074 0.088 0.19 0.102 0.046 0.106 0.136 0.049 0.165 0.148 0.052 0.073 0.175 0.082 0.079 0.36 0.67 0.47 0.64 0.7 0.29 0.18 0.2 0.14 0.28 0.22 0.3 0.21 0.34 0.39 0.44 0.3 0.41 0.2 0.16 0.15 0.39 0.27 0.34 0.3 0.2 0.15 0.21 0.31 0.25 Adenosine triphosphate 0.095 0.088 0.13 0.121 0.115 0.103 0.071 0.068 0.052 0.047 0.063 0.052 0.043 0.024 0.043 0.032 0.021 0.025 0.068 0.052 0.03 0.052 0.026 0.006 0.037 0.042 0.044 0.019 0.027 0.008 1.23 0.45 0.2 0.28 0.36 0.83 0.94 0.98 0.93 0.45 0.76 0.65 0.05 0.1 0.32 0.28 0.25 0.31 0.82 0.61 0.65 0.38 0.35 0.26 0.45 0.9 0.4 0.58 0.22 0.58 6-Phosphogluconic acid 6.358 6.228 5.414 5.636 6.52 5.401 9.167 8.113 10.337 7.143 9.69 8.031 2.464 3.279 2.524 3.819 3.272 3.557 10.584 6.462 6.31 6.622 2.952 5.588 4.987 7.275 7.279 5.152 6.184 5.489 0.47 0.38 0.17 0.16 0.19 0.24 0.37 0.29 0.35 0.21 0.19 0.25 0.11 0.1 0.12 0.1 0.09 0.11 0.27 0.26 0.18 0.11 0.15 0.17 0.38 0.19 0.23 0.2 0.09 0.24 D-Ribose 5-phosphate 0.722 0.707 0.759 0.621 0.608 0.809 1.006 1.027 1.101 0.95 1.02 0.988 0.598 0.492 0.46 0.486 0.447 0.459 0.688 0.492 0.468 0.532 0.453 0.637 0.552 0.717 0.635 0.634 0.524 0.675 2.26 2.06 1.39 1.27 1.25 1.2 1.57 1.81 1.23 1.23 1.19 1.37 2.44 1.72 1.9 1.45 1.15 1.54 1.15 1.3 1.79 1.46 1.19 1.57 2.15 2.53 1.65 1.49 1.24 1.92 Ribose 1,5-bisphosphate 0.213 0.216 0.234 0.187 0.168 0.236 0.2625 0.23284 0.22692 0.28169 0.26622 0.24045 0.17 0.176 0.179 0.141 0.158 0.121 0.274 0.236 0.142 0.238 0.222 0.275 0.201 0.216 0.172 0.176 0.204 0.19 0.03 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.01 0.01 0.01 D-Sedoheptulose 7-phosphate 0.57 0.63 0.634 0.693 0.843 0.792 1.008 0.9 1.385 1.394 1.199 1.375 0.374 0.396 0.274 0.422 0.313 0.435 0.768 0.914 0.498 0.598 0.773 0.297 0.467 0.521 0.688 0.626 0.673 0.723 0.4 0.11 0.09 0.04 0.06 0.14 0.22 0.15 0.19 0.07 0.11 0.11 0.08 0.08 0.05 0.1 0.05 0.07 0.11 0.13 0.05 0.04 0.1 0.05 0.13 0.23 0.1 0.14 0.07 0.13 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name KEGG ID Pubchem ID D-Glucose C00031 5793 Glucose 6-phosphate C00092 5958 Fructose 1,6-bisphosphate C00354 445557 3-Phosphoglyceric acid C00597 724 Phosphoenolpyruvic acid C00074 1005 Pyruvic acid C00022 1060 L-Lactic acid C00256 61503 Citric acid C00158 311 Succinic acid C00042 1110 Fumaric acid C00122 444972 Malic acid C03668 525 Adenosine monophosphate C00020 6083 Adenosine triphosphate C00002 5957 6-Phosphogluconic acid C00345 91493 D-Ribose 5-phosphate C00117 439167 Ribose 1,5-bisphosphate C01151 14035695 D-Sedoheptulose 7-phosphate C00281 22833559 METABOLITES_END #END